CVS Pharmacy(R) and MinuteClinic(R) Now Offering Updated Flu Vaccines Nationwide
CVS Health survey finds more than 60 percent of consumers say they are likely to get a flu shot this...
Vaccine
Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our...
Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and...
Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our...
Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer
K1.1 mRNA demonstrated tumor-suppressing activity as a single agent in multiple in vivo hepatocellular carcinoma modelsProgram targets a tumor suppressor...
The Emmes Group Appoints Dr. Rama Kondru as Chief Executive Officer
ROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- The Emmes Group today announced that its Board of Directors has appointed Dr....
The Emmes Group Appoints Dr. Rama Kondru as Chief Executive Officer
ROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- The Emmes Group today announced that its Board of Directors has appointed Dr....
EVERGLADE WELCOMES FORMER ARPA-H SCIENTIFIC ADVISOR KATE TEFFER TO EXPAND FEDERAL HEALTH RESEARCH CAPABILITIES
Teffer brings firsthand experience shaping and evaluating early ARPA-H research concepts, alongside a decade of federal biomedical R&D advisory work.HOUSTON,...
Rapid Dose Therapeutics and Aavishkar Granted Monolayer QuickStrip(TM) Nicotine Patent, Advancing RDT’s Global Commercialization Strategy
Second granted nicotine oral-film patent strengthens RDT's intellectual-property portfolio and its collaboration with a global nicotine industry leader, advancing the...
Bioz and InvivoGen Elevate Scientific Discovery with an Expanded Digital Research Experience
PALO ALTO, CA / ACCESS Newswire / August 19, 2026 / Bioz, Inc., the scientific marketing platform that transforms peer-reviewed...
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
SHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
Zomedica Announces Strategic Collaboration with Boehringer Ingelheim Animal Health Canada Inc. to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform
Collaboration with one of the world's largest animal health companies expected to accelerate TRUFORMA adoption, expand installed base, and drive...
Ember LifeSciences appoints James Braithwaite as Chief Product Officer
Innovation executive to lead product strategy and developmentLOS ANGELES, Aug. 11, 2026 /PRNewswire/ -- As Ember LifeSciences, Inc. continues to...
Boehringer Ingelheim expands equine health pipeline with acquisition of Evax AG
Boehringer headquarters Boehringer headquarters, Ingelheim, Germany Boehringer Ingelheim announced today that it has acquired Evax AG, a Swiss biotech company focused on equine health....
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
SHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
ABL Ascend Advanced Therapies Names Suman Subramanian as Chief Business Officer
ROCKVILLE, MD / ACCESS Newswire / August 10, 2026 / ABL Inc and Ascend Advanced Therapies today announced the appointment...
Internationally Recognized Johns Hopkins Oncologist Dr. Stephen J. Noga Joins Immunocine as Chief Medical Officer
Veteran Physician-Scientist and Cellular Therapy Expert to Help Advance the Future of Personalized Cancer Immunotherapy In this video, Dr. Matt...
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved productCompany expects supply to be available in select retailers in...
Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna’s Investigational Vaccine Against Bundibugyo Ebolavirus
Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines...
Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
Reports second quarter revenue of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(1.97)Reiterates plan to...